PC-002 (Sepantronium Bromide) Enhances the Antitumor Efficacy of Anti-CD20 Antibody By CD20 Upregulation

Vernon C. Jiang, Xiang Li, Na He, Yan Lv, Haiyue Wang, Ming Zhang, Heiyan Zhai, Zhen Yang, Yi Yang, Dagang Guo, Zhixiang Cao, Yiyou ChenBlood 2024 · DOI

Abstract

Introduction: Anti-CD20 monoclonal antibodies have become a standard therapy for B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL). However, despite the high response rate of anti-CD20 monoclonal antibody, many DLBCL and BL patients suffer recurrent disease within 5 years. One potential mechanism of anti-CD20 antibody resistance is loss or down-regulation of CD20 expression. It has been reported that CD20 up-regulation was observed following c-Myc inactivation [1]. PC-002 down-regulates Myc protein by blocking the deubiquitination activity of USP7 [2]. Therefore, the aim of this study is to define whether PC-002 can upregulate CD20 expression by inhibiting c-Myc protein and enhance the antitumor efficacy of anti-CD20 antibody. Material and Methods: The DLBCL and BL cells (SU-DHL-10 and RAMOS) were treated with PC-002 in vitro. Then expression of CD20 mRNA was assayed by qRT-PCR. Next, P493 cells with tet-off Myc transgene were used to further confirm the effect of PC-002 on CD20 expression. P493 tet-off cells were treated with tetracycline to suppress the expression of c-Myc (Myc-off). PC-002 was used to treat Myc-on (without tetracycline) and Myc-off P493 cells, then expression of CD20 mRNA was assayed by qRT-PCR. Furthermore, mouse xenografts (RAMOS, SU-DHL-4, SU-DHL-10 and OCI-LY7) were established to evaluate the efficacy of YM155 (2 mg/kg, 168-hour-infusion) in combination with anti-CD20 antibody, including Rituximab, Ripertamab and Ofatumumab in vivo. In addition, a murine DLBCL bone metastasis model was established by injecting RFP/luciferase-expressing NAMALWA (NAMALWA-RFP/Luc) cells via the caudal artery. The bone metastasis model was used to examine the efficacy of the PC002/anti-CD20 treatment. Tumor growth was monitored with an in vivo small animal imaging system. Results: PC-002 upregulated CD20 mRNA expression in a dose-dependent manner in BL and DLBCL cells. Such effect was diminished in Myc-off P493 cells. PC-002 in combination with anti-CD20 antibody Rituximab resulted in complete arrest of tumor growth in SU-DHL-10 xenograft models. More strikingly, 4 out of 6 mice in this group showed complete tumor regression by day 21. In contrast, neither agent alone could suppress tumor growth. Similar result was observed in OCI-LY7 xenograft model. The combination effect was further extended to other anti-CD20 antibodies, including Ripertamab and Ofatumumab. Mice with RAMOS or OCI-LY7 xenograft showed more pronounced tumor regression after receiving antibody-PC-002 combination treatment, compared to either agent alone. To further mimic clinical disease of bone metastasis, NAMALWA cells were stably transfected with RFP/Luc reporter and established bone metastasis model via tail artery inoculation. PC-002 and Rituximab combination demonstrated superior efficacy compared to either drug alone. Moreover, the up-regulation of CD20 after PC-002 treatment in RFP/Luc cells was confirmed by whole transcriptome analysis. These results indicate that PC-002 enhances the efficacy of anti-CD20 antibody by downregulating c-Myc, and support the planned clinical investigation of the combination of PC002 with an anti-CD20 antibody such as rituximab in patients with relapsed/refractory c-Myc driven Burkitt lymphoma or diffuse large B-cell lymphoma. Conclusion: In conclusion, our preclinical data highlight the potent anti-tumor effects of PC-002 in combination with anti-CD20 antibody in patients with DLBCL and BL, and warrant the planned clinical investigation of the combination of PC002 with rituximab in patients with relapsed/refractory c-Myc driven Burkitt lymphoma or diffuse large B-cell lymphoma. References: 1. Yu D, Dews M, Park A, Tobias JW, Thomas-Tikhonenko A. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res. 2005 Jun 15;65(12):5454-61. doi: 10.1158/0008-5472.CAN-04-4197. PMID: 15958595; PMCID: PMC1490323. 2. Li, X., et al., YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor. European Journal of Pharmaceutical Sciences, 2023. 181.
BibTeX
@inproceedings{jiang2024pc,
  author = {Vernon C. Jiang and Xiang Li and Na He and Yan Lv and Haiyue Wang and Ming Zhang and Heiyan Zhai and Zhen Yang and Yi Yang and Dagang Guo and Zhixiang Cao and Yiyou Chen},
  title = {{PC-002 (Sepantronium Bromide) Enhances the Antitumor Efficacy of Anti-CD20 Antibody By CD20 Upregulation}},
  booktitle = {Blood},
  year = {2024},
  doi = {10.1182/blood-2024-209648},
}

Loading related content...

Figure